Aziyo Biologics, Sientra team on SimpliDerm for soft tissue reconstruction

Aziyo Biologics (AZYO) and Sientra (SIEN) announced they have entered into an agreement to expand the distribution of Aziyo’s SimpliDerm product line. Under the agreement terms, Aziyo will grant Sientra certain non-exclusive rights in the United States to market, sell and distribute SimpliDerm for select use in reconstruction surgery. "At Aziyo, our mission is to improve compatibility between medical devices and the patients they serve. With this partnership, we significantly expand women’s access to biologic solutions necessary for successful reconstruction procedures," said Randy Mills, Ph.D., President and Chief Executive Officer of Aziyo Biologics. "We are excited to partner with Sientra, a proven commercial company that brings a highly-specialized commercial team with reach and relationships to help drive growth of the SimpliDerm portfolio in reconstructive surgery. This agreement is intended to help drive meaningful revenue growth and support our strategy of quickly and profitably expanding the reach of our proprietary biologics platforms." SimpliDerm is a pre-hydrated human acellular dermal matrix or hADM, that uses a proprietary process to preserve key growth factors of native dermis that support faster integration and more rapid revascularization while demonstrating a lower risk of inflammatory response. Due to this unique process, SimpliDerm has been able to provide a pliable, conforming matrix in a ready-to-use format and achieve a sterility assurance level of 10-6. "At Sientra, we believe that putting the best products in the hands of the most qualified surgeons leads to the most optimal results. The partnership with Aziyo allows our customer to access the innovative SimpliDerm portfolio to provide the industry’s most compelling reconstruction portfolio," said Ron Menezes, President and Chief Executive Officer of Sientra. "The addition of SimpliDerm to our portfolio fits perfectly with our strategy of being the leader in reconstruction, while enhancing our path to profitability." SimpliDerm is to be used for the repair or replacement of damaged or insufficient integumental tissue or for other homologous uses of human integument.